Medical, surgical, radiation, and interventional oncology all play vital roles in delivering care to patients battling liver cancer. How do we optimize outcomes when so many specialties have something to offer the same patient? The answer is collaborative oncology. Dr. Robert Martin (Director of Surgical Oncology, University of Louisville) and pioneer in liver-directed therapies, joins host Dr. Sabeen Dhand to discuss a collaborative approach to oncology and recent advances in locoregional therapy.

---

This podcast is supported by:

RADPAD® Radiation Protection

https://www.radpad.com/

---

SYNPOSIS

Dr. Martin discusses the importance of a growth mindset in advancing medical techniques and fostering collaborations between specialists. He then shares insights into minimally invasive procedures, such as microwave ablation and irreversible electroporation (IRE). The doctors also touch on the evolution of liver cancer treatments, emphasizing the significance of clinical trials on the horizon. To conclude, Dr. Martin encourages young professionals in surgery and interventional radiology to stay open-minded, be life-long learners, and find synergistic ways to integrate new technologies into patient care.

---

TIMESTAMPS

00:00 - Introduction

02:31 - Dr. Martin’s Background and Career Path

06:18 - Evolution of Liver Directed Therapies

10:12 - Collaboration Between Specialties

18:34 - Clinical Trials and Emerging Therapies

36:08 - Advice for Young Professionals

39:15 - Conclusion

---

RESOURCES

Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of HCC:

https://clinicaltrials.gov/study/NCT05953337?term=NCT05953337&rank=1

Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS (INJECTABL-1):

https://clinicaltrials.gov/study/NCT05688280

Immunophotonics, CIRSE, and Next Research Announce Innovative Phase 2/3 Clinical Trial: INJECTABL-3:

https://immunophotonics.com/news/immunophotonics-cirse-and-next-research-announce-innovative-phase-2-3-clinical-trial-injectabl-3/

21: Jeremiah Watkins